Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexsero (4CMenB) Vaccine in Healthy Adolescents
NCT00297817Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2006
- Primary completion
- Apr 2007
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Multicomponent meningococcal B vaccine in meningococcal disease, sponsored by Novartis. Primary endpoint: Serum Bactericidal Activity. Started Feb 2006; status: completed.
02
Drugs
Multicomponent meningococcal B vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00297817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297817.